GlassScriptPhysician profile
Dean Adkins
NPI 1730434747
$744.38
in general payments reported to CMS, 2019-2025
14 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $84.81 · 2023: $227 · 2024: $174 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $256.18 | 2022-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $158.51 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $69.77 | 2023 | Farxiga, Evusheld, Breztri |
| Exact Sciences Corporation | $38.66 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $33.52 | 2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $33.37 | 2022-2023 | Yupelri |
| Pfizer INC. | $29.91 | 2023 | |
| Averitas Pharma INC. | $21.71 | 2025 | Qutenza |
| Hologic Sales and Service, LLC | $18.78 | 2023 | Aptima, Thinprep 2000 Processor, Third Wave |
| Astellas Pharma US INC | $18.17 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $16.95 | 2024 | Zoryve |
| Biogen, INC. | $16.94 | 2025 | Skyclarys |
| Otsuka America Pharmaceutical, INC. | $16.82 | 2025 | Rexulti |
| Viatris Specialty LLC | $15.09 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.